• The word in context (phrases, idioms)
• A topic called "Feuer" (a song, brand, film, etc.)
• Something else entirely

COPD - Disease Explanation and Cause of Symptoms

What is COPD?

• Harrison's Principles of Internal Medicine 22E, p. 461

Causes and Risk Factors

1. Cigarette Smoking (primary cause)

2. Biomass Fuel Exposure

3. Air Pollution

4. Early Life Factors

• Maternal smoking during pregnancy reduces postnatal lung development
• Childhood environmental tobacco smoke exposure reduces lung growth

5. Genetics - Alpha-1 Antitrypsin (α1AT) Deficiency

• A proven genetic risk factor
• The Z allele of the SERPINA1 gene leads to markedly reduced α1AT levels
• PiZ homozygotes develop early-onset emphysema, especially if they also smoke
• About 1 in 3,000 individuals in the US inherits severe α1AT deficiency
• Only ~1% of COPD patients have this as the contributing cause, but it proves how powerful genetic factors can be
• Harrison's 22E, p. 645-658

Pathogenesis - How Disease Develops

Step-by-step mechanism:

• Macrophages and epithelial cells release proteinases (esp. neutrophil elastase and matrix metalloproteinases like MMP-12)
• These degrade the extracellular matrix (elastin, collagen) supporting airways and alveoli
• The key concept: elastase:anti-elastase imbalance - when α1AT (the natural inhibitor of neutrophil elastase) is insufficient, unchecked proteolysis destroys lung tissue
• MMP-12 and neutrophil elastase mutually inactivate each other's inhibitors, creating a destructive positive feedback loop

• Cigarette smoke overwhelms antioxidant defenses
• Oxidant-induced inactivation of HDAC2 shifts chromatin balance, enabling transcription of proinflammatory cytokines (IL-8, TNF-α) and recruiting more neutrophils
• NRF2 (antioxidant regulator) and SOD3 are implicated in emphysema pathogenesis

• Alveolar wall perforations lead to coalescence into large emphysematous air spaces
• Loss of elastic recoil reduces the lung's ability to push air out
• Small airway dropout and loss of lung microvasculature occur in advanced COPD

• Lymphoid follicles with B and T cells form around airways
• Antibodies against elastin fragments and IgG autoantibodies against pulmonary epithelium develop
• TH1 and TH17 cells amplify chronic inflammation
• Critically: inflammation continues even after smoking cessation in susceptible individuals, explaining why COPD can progress despite quitting
• Harrison's 22E, p. 509-563

Specific Airway Changes and Symptom Causes

Large Airway Disease → Cough and Sputum Production

• Cigarette smoke causes mucus gland enlargement and goblet cell hyperplasia
• Goblet cells increase in number and extend further into the bronchial tree
• Bronchi undergo squamous metaplasia, disrupting mucociliary clearance
• Loss of cilia (from smoking) prevents normal mucus clearance
• Result: chronic productive cough (defining chronic bronchitis)

Small Airway Disease → Airflow Obstruction and Dyspnea

• The major site of resistance is in airways ≤2 mm diameter
• Goblet cell metaplasia replaces surfactant-secreting club cells
• Luminal narrowing by fibrosis, mucus, edema, and inflammatory cell infiltration
• Reduced surfactant → increased surface tension → airway collapse on expiration
• Smooth muscle hypertrophy
• Advanced disease: actual dropout (loss) of small airways

Emphysema → Air Trapping, Barrel Chest, Hyperinflation

• Destruction of alveolar walls → loss of elastic recoil
• Without elastic recoil, airways collapse during expiration → air trapping
• Residual volume and TLC increase → barrel chest and flat diaphragm
• Loss of gas exchange surface → reduced DLCO → hypoxemia

Clinical Features and Their Mechanism

• Harrison's Principles of Internal Medicine 22E, pp. 696-714
• Fishman's Pulmonary Diseases and Disorders, p. 3163-3168

Lung Function Changes

• FEV1/FVC ratio < 0.70 - hallmark obstructive pattern (post-bronchodilator)
• FEV1 reduced - correlates with dyspnea severity, exacerbation frequency, and mortality
• Increased TLC, RV, FRC - from air trapping (hyperinflation)
• Reduced DLCO - from emphysematous destruction of alveolar surface area
• GOLD staging uses FEV1 % predicted (Grades 1-4)
• BODE index (BMI, Obstruction, Dyspnea, Exercise) better predicts mortality than FEV1 alone

Summary Diagram

Smoking / Inhaled irritants
         ↓
Airway inflammation (neutrophils, macrophages, CD8+ T cells)
         ↓
Proteinase release (neutrophil elastase, MMP-12)
+ Oxidative stress
         ↓
Large airways: goblet cell hyperplasia → Cough, sputum
Small airways: fibrosis, narrowing, dropout → Airflow obstruction, Dyspnea
Alveoli: elastic tissue destruction → Emphysema, air trapping, ↓gas exchange
         ↓
Hyperinflation → barrel chest, diaphragm flattening
V/Q mismatch → hypoxemia → cor pulmonale
Systemic inflammation → cachexia, muscle wasting

HPI for COPD - Template + Sample

TEMPLATE

[Patient identifier] is a [age]-year-old [sex], [smoking status], 
with a known/new diagnosis of COPD, who presents with a 
[duration]-history of [chief complaint].

ONSET:
The symptoms began [acutely/gradually] approximately [time] ago.
[Was there a trigger? e.g., recent URTI, cold weather, new exposure]

MAIN SYMPTOMS (ask about each):
1. Dyspnea
   - At rest / on exertion / nocturnal?
   - Change from baseline? (e.g., "worse than usual")
   - MRC dyspnea grade:
     Grade 1 - breathless on strenuous exertion
     Grade 2 - breathless when hurrying on level ground
     Grade 3 - walks slower than peers / stops after 100 m
     Grade 4 - stops after a few minutes on level ground
     Grade 5 - too breathless to leave the house / dress

2. Cough
   - Productive or dry?
   - Frequency (constant, morning only)?
   - Duration (chronic >3 months?)

3. Sputum
   - Color: clear / white / yellow / green / blood-tinged
   - Volume: teaspoons/day
   - Change from baseline (increased amount, purulence)?

4. Wheeze
   - Present? Continuous or episodic?

ASSOCIATED SYMPTOMS:
- Fever / chills (suggests infective exacerbation)
- Chest tightness / chest pain
- Hemoptysis (red flag - exclude lung Ca, PE)
- Ankle swelling / orthopnea (suggests cor pulmonale / HF)
- Weight loss / anorexia (suggests cachexia or malignancy)
- Confusion / drowsiness (CO2 retention - hypercapnic failure)

SEVERITY INDICATORS:
- Able to complete full sentences?
- Sleeping / eating affected?
- Any hospital admissions in the past?
- Number of exacerbations in the last 12 months?
- Previous intubation / ICU admission?

RELEVANT HISTORY:
- Smoking: pack-year history (packs/day × years smoked)
- Occupational/biomass exposure
- Current medications (inhalers - SABA, LAMA, ICS/LABA?)
- Compliance with inhalers
- Home oxygen use?
- Last spirometry (FEV1 %)
- Vaccinations (flu, pneumococcal, COVID)

DIFFERENTIAL CONSIDERATIONS:
- Recent change in weather / allergen exposure (asthma?)
- Leg pain/swelling (PE?)
- Cardiac history (heart failure?)

SAMPLE HPI - COPD Exacerbation

Mr. Ahmed is a 65-year-old male, an ex-smoker with a 40 pack-year history (quit 5 years ago), with a known diagnosis of GOLD Grade 3 COPD on dual bronchodilator therapy (tiotropium + salmeterol/fluticasone). He presents with a 3-day history of worsening breathlessness.

Onset: The breathlessness began gradually 3 days ago following an upper respiratory tract infection with nasal congestion and sore throat. No clear trigger prior to the URTI.

Dyspnea: He reports his breathlessness is significantly worse than his usual baseline. He was previously able to walk on flat ground for approximately 200 meters (MRC Grade 3), but for the past 2 days he has been unable to walk from the bedroom to the bathroom without stopping (MRC Grade 4-5). He is unable to complete full sentences.

Cough: He has a chronic morning cough productive of white sputum for several years. Over the past 3 days, the sputum has increased in volume and turned yellow-green, consistent with purulent change.

Wheeze: He reports audible wheeze on expiration, worse than his usual.

Associated symptoms: He denies fever but reports mild chills. No hemoptysis. No chest pain. Mild bilateral ankle swelling noted (chronic, unchanged). No confusion or drowsiness. Appetite reduced for 2 days.

Exacerbation history: He has had 2 exacerbations in the past 12 months, one requiring a 3-day hospital admission. No previous ICU admission or intubation.

Medications and compliance: He uses his inhalers regularly. His last FEV1 was 42% predicted (3 months ago). He is not on home oxygen. He received the influenza vaccine this season but has not had the pneumococcal vaccine.

Impression: This presentation is consistent with an acute exacerbation of COPD (AECOPD), likely infective in etiology based on the increased sputum purulence and preceding URTI. Severity indicators include inability to complete sentences, inability to mobilize, and failure to improve with usual bronchodilators.

Key Acronym for HPI Structure - OLDCARTS

What Makes COPD HPI "Positive" (i.e., Key Positives to Specifically Document)

1. Smoking history - pack-years (most important risk factor)
2. Progressive dyspnea - worse than baseline
3. Change in sputum - increased volume + purulence = infective exacerbation
4. Wheeze - especially new or worsened
5. Prior exacerbations/admissions - indicates severity and prognosis
6. Non-compliance with inhalers - common precipitant
7. Cor pulmonale signs - ankle swelling, orthopnea

How to Rule Out Cardiac Causes in a Respiratory Presentation

Step 1 - History (Symptoms That Point Cardiac)

Compare: Respiratory Clues That Point Away from Cardiac

• Morning productive cough (chronic bronchitis)
• Wheeze triggered by cold air, allergens, exercise
• Long smoking history
• Purulent sputum (infective)
• Symptom-free periods (asthma)

Important: Classic HF symptoms like orthopnea and PND have LR+ of only 2.2-2.6 - they are not specific enough alone. Advanced HF can be present even WITHOUT crackles, edema, or raised JVP in 42% of patients.

• Symptom to Diagnosis, 4th Edition, p. 4466-4472

Step 2 - Physical Examination (High-Value Signs)

Respiratory Signs That Favor Pulmonary (Not Cardiac)

• Prolonged expiratory phase + expiratory wheeze - obstructive
• Barrel chest + hyper-resonance - emphysema
• Bronchial breathing / reduced breath sounds - consolidation / effusion
• Clubbing - fibrosis, bronchiectasis, malignancy (NOT COPD)

Key point: S3 gallop (LR+ 11) and JVD (LR+ 5.1) are the two most diagnostically powerful bedside findings for ruling IN heart failure.

• Symptom to Diagnosis, 4th Edition, p. 4473-4498

Step 3 - Investigations (The Workup)

A. Chest X-Ray

Pulmonary venous congestion and interstitial edema on CXR are the most diagnostically useful findings - specificity 96-97%, LR+ 12.

• Symptom to Diagnosis, 4th Edition, p. 4525

B. BNP / NT-proBNP (Most Useful Single Test)

• BNP is not specific to HF alone - also elevated in PE, renal failure, sepsis, and RV strain from cor pulmonale in COPD
• Obesity lowers BNP levels (may falsely reassure)
• Renal failure and age raise BNP levels (may falsely alarm)
• A low BNP (<100) is your best tool to exclude cardiac dyspnea (sensitivity 93%, LR- 0.11)
• Goldman-Cecil Medicine, p. 2520-2524; Symptom to Diagnosis, p. 4557-4575

C. ECG

• Not diagnostic for HF alone, but rarely completely normal in HF
• Look for: LVH (voltage criteria), Q waves (old MI), AF, LBBB, ST changes
• Normal ECG makes significant cardiac dysfunction less likely
• LBBB + dyspnea = suspect HFrEF until proven otherwise

D. Echocardiogram (Definitive Test)

• Measures ejection fraction (EF) - distinguishes HFrEF (<40%) from HFpEF (>50%)
• Identifies wall motion abnormalities (ischemic cardiomyopathy)
• Assesses valve disease, diastolic function, pericardial effusion
• Quantifies pulmonary artery pressure (cor pulmonale from chronic lung disease)

E. POCUS (Point-of-Care Ultrasound) at Bedside

• Residents with limited training can identify EF <40% with sensitivity 94%, specificity 94% (LR+ 15.7, LR- 0.06)
• B-lines on lung ultrasound (comet-tail artifacts from interstitial edema): LR+ 7.4 for acute HF - very useful at bedside
• Symptom to Diagnosis, 4th Edition, p. 4577-4579

Step 4 - The Clinical Framework: Key Differences at a Glance

Practical Approach at the Bedside

Patient presents with DYSPNEA
           ↓
1. History: Orthopnea? PND? Cardiac risk factors? Smoking? Wheeze triggers?
           ↓
2. Exam: JVD? S3? Displaced apex? vs. Wheeze? Hyperinflation? Prolonged expiration?
           ↓
3. CXR: Cardiomegaly / Kerley B / upper lobe diversion? vs. Hyperinflation?
           ↓
4. BNP: < 100 → cardiac unlikely | > 400 → cardiac likely
           ↓
5. ECG: LVH? Old MI? AF? LBBB?
           ↓
6. Spirometry: Obstructive pattern → respiratory; Normal → consider cardiac
           ↓
7. Echo: Definitive - confirms or excludes cardiac cause

Bottom line: The single most powerful test to rule OUT cardiac dyspnea is BNP < 100 pg/mL (LR- 0.11). The most specific bedside signs to rule IN cardiac are S3 gallop (LR+ 11) and JVD (LR+ 5.1). When in doubt, do an echo.